Luminal B型乳腺癌新辅助化疗效果与影响因素分析

发布时间：2018-03-27 19:36

本文选题：Luminal　切入点：B型乳腺癌　出处：《广东医学》2017年22期

【摘要】：目的探讨不同亚型Luminal B型乳腺癌新辅助化疗的效果及病理完全缓解(p CR)的影响因素,为临床干预及预后评估提供参考。方法采用回顾性调查方法,收集行新辅助化疗的Luminal B型乳腺癌患者148例,以HER2表达情况分为HER2阴性亚型与HER2阳性亚型,采用X~2检验分析两组新辅助化疗的效果;以是否pCR分为pCR组及非p CR组,采用X~2检验及非条件逐步logistic回归分析影响因素。结果在148例患者中,HER2阴性亚型93例,HER2阳性亚型55例,两组治疗方案、治疗周期、pCR率的差异有统计学意义(P0.05);p CR组14例(HER2阴性亚型5例,HER2阳性亚型9例),非pCR组134例;影响pCR的因素有:雌激素受体(ER)状态、HER2状态、Ki67指数(P0.05)。结论 Luminal B型HER2阳性亚型乳腺癌的新辅助化疗反应性好于HER2阴性,在治疗有效的前提下可适当延长化疗周期以提高p CR率。ER阴性或低表达、HER2阳性、Ki67高表达对新辅助化疗疗效具有一定的预测价值。
[Abstract]:Objective to investigate the effect of neoadjuvant chemotherapy for different subtypes of Luminal B breast cancer and the influencing factors of complete pathological remission (CR), and to provide a reference for clinical intervention and prognosis evaluation. 148 patients with Luminal B breast cancer receiving neoadjuvant chemotherapy were divided into HER2 negative subtype and HER2 positive subtype according to the expression of HER2. The effect of neoadjuvant chemotherapy was analyzed by X2 test, and pCR was divided into pCR group and non-pCR group according to whether pCR was divided into pCR group and non-pCR group. Results among 148 patients, 93 cases of negative subtype of HER2 had positive subtype of HER2, 55 cases had positive subtype of HER2. The difference of the rate of pCR in the treatment cycle was statistically significant. There were 14 cases of HER2 negative subtype in 14 cases of HER2 negative subtype, 9 cases of positive subtype of HER2 in non-HER2 group, and 134 cases of non-HER2 group. The influencing factors of pCR were as follows: ER _ 2 status and Ki67 index P0.050.Conclusion Neoadjuvant chemoreactivity of Luminal B HER2 positive subtype breast cancer is better than that of HER2 negative. On the premise of effective treatment, the chemotherapy cycle can be extended appropriately to increase the pCR rate. ER negative or low expression of HER2 positive Ki67 high expression has certain predictive value for neoadjuvant chemotherapy efficacy.
【作者单位】：广东省中医院乳腺科;广东省中医院芳村医院急诊科;
【基金】：广东省中医药局建设中医药强省科研课题(编号:20151226)
【分类号】：R737.9

【相似文献】